New Small Molecules, ISA27 and SM13, Inhibit Tumour Growth Inducing Mitochondrial Effects of P53

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Nov 26

PMID 25422906

Citations 10

Authors

D Sorriento

C Del Giudice

A Bertamino

M Ciccarelli

I Gomez-Monterrey

P Campiglia

E Novellino

M Illario

B Trimarco

N De Luca

G Iaccarino

Affiliations

Soon will be listed here.

Abstract

Background: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-type (WT) tumour cells. The aim of this study was to verify the effectiveness of these compounds in tumours carrying a mutated form of p53 gene with no transcriptional activity.

Methods: In vitro we evaluated the effectiveness of our compounds in cancer cell lines carrying WT, mutated and null p53 gene. In vivo study was performed in Balb/c nude mice and the mitochondrial-dependent apoptotic signalling was evaluated by western blot.

Results: Both ISA27 and SM13 reduced cell proliferation and induced apoptosis in vitro in cells carrying either p53 WT or mutated gene, suggesting that its effect is independent from p53 transcriptional activity. On the contrary, SM13 had no effect in a p53 null cell line. In vivo, ISA27 and SM13 induced cancer cell death in a dose-dependent manner through the activation of the mitochondrial-dependent death signalling in p53-mutated cells. In vivo, SM13 reduced tumour growth.

Conclusions: Our study proposes SM13 as anticancer compound to use for the treatment of p53-dependent tumours, even in the absence of p53 transcriptional activity.

Citing Articles

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.

Son B, Lee W, Kim H, Shin H, Park H Cell Death Dis. 2024; 15(9):696.

PMID: 39349424 PMC: 11442590. DOI: 10.1038/s41419-024-07077-8.

Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines.

Gambardella J, Santulli G, Fiordelisi A, Cerasuolo F, Wang X, Prevete N Cell Mol Life Sci. 2023; 80(11):323.

PMID: 37819449 PMC: 10567889. DOI: 10.1007/s00018-023-04922-5.

Synthesis and Biological Evaluation of Novel -Indolinones with Anticancer Activity.

Ivanenkov Y, Kukushkin M, Beloglazkina A, Shafikov R, Barashkin A, Ayginin A Molecules. 2023; 28(3).

PMID: 36770991 PMC: 9919490. DOI: 10.3390/molecules28031325.

Targeting GRK5 for Treating Chronic Degenerative Diseases.

Marzano F, Rapacciuolo A, Ferrara N, Rengo G, Koch W, Cannavo A Int J Mol Sci. 2021; 22(4).

PMID: 33671974 PMC: 7919044. DOI: 10.3390/ijms22041920.

Exploiting GRK2 Inhibition as a Therapeutic Option in Experimental Cancer Treatment: Role of p53-Induced Mitochondrial Apoptosis.

Gambardella J, Fiordelisi A, Santulli G, Ciccarelli M, Cerasuolo F, Sala M Cancers (Basel). 2020; 12(12).

PMID: 33256128 PMC: 7760517. DOI: 10.3390/cancers12123530.

References

Wolf D, Rotter V . Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A. 1985; 82(3):790-4. PMC: 397132. DOI: 10.1073/pnas.82.3.790. View

Iaccarino G, Izzo R, Trimarco V, Cipolletta E, Lanni F, Sorriento D . Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clin Pharmacol Ther. 2006; 80(6):633-45. DOI: 10.1016/j.clpt.2006.09.006. View

Green D, Kroemer G . Cytoplasmic functions of the tumour suppressor p53. Nature. 2009; 458(7242):1127-30. PMC: 2814168. DOI: 10.1038/nature07986. View

Santulli G, Basilicata M, De Simone M, Del Giudice C, Anastasio A, Sorriento D . Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit. J Transl Med. 2011; 9:7. PMC: 3027097. DOI: 10.1186/1479-5876-9-7. View

Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli G, Cimini V . The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci U S A. 2008; 105(46):17818-23. PMC: 2584738. DOI: 10.1073/pnas.0804446105. View

Brown C, Lain S, Verma C, Fersht A, Lane D . Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009; 9(12):862-73. DOI: 10.1038/nrc2763. View

Chen J, Wu X, Lin J, Levine A . mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996; 16(5):2445-52. PMC: 231233. DOI: 10.1128/MCB.16.5.2445. View

Ha J, Shin J, Yoon M, Lee M, He F, Bae K . Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J Biol Chem. 2013; 288(10):7387-98. PMC: 3591646. DOI: 10.1074/jbc.M112.400754. View

Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F . Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One. 2013; 8(8):e72281. PMC: 3747081. DOI: 10.1371/journal.pone.0072281. View

10.

Bourdon J, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas D . p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005; 19(18):2122-37. PMC: 1221884. DOI: 10.1101/gad.1339905. View

11.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

12.

Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87(1):99-163. DOI: 10.1152/physrev.00013.2006. View

13.

Blagosklonny M, Giannakakou P, Wojtowicz M, Romanova L, Ain K, Bates S . Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 1998; 83(7):2516-22. DOI: 10.1210/jcem.83.7.4984. View

14.

Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y . Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005; 280(19):19166-76. DOI: 10.1074/jbc.M410691200. View

15.

Vousden K, Lu X . Live or let die: the cell's response to p53. Nat Rev Cancer. 2002; 2(8):594-604. DOI: 10.1038/nrc864. View

16.

Kim S, Chae H, Bach J, Lee M, Kim K, Lee W . P53 mediates ceramide-induced apoptosis in SKN-SH cells. Oncogene. 2002; 21(13):2020-8. DOI: 10.1038/sj.onc.1205037. View

17.

Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C . Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 2005; 65(6):2108-14. DOI: 10.1158/0008-5472.CAN-04-2935. View

18.

Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P . p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003; 11(3):577-90. DOI: 10.1016/s1097-2765(03)00050-9. View

19.

Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-9. DOI: 10.1038/387296a0. View

20.

Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G . Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Hypertension. 2012; 60(1):129-36. DOI: 10.1161/HYPERTENSIONAHA.111.189605. View